FDA iffy on Abott's Humira for bowel disease; Forest makes it official, Icahn won one;

> Just ahead of an FDA advisory panel decision Tuesday, FDA staff suggested that Abbott Laboratories ($ABT) may need to do more testing on whether its cornerstone drug, Humira, provides any benefit in treating inflammatory bowel disease. Story

> The U.K.'s European Medicines Agency (EMA) has issued a warning about Pacira Pharmaceuticals' brain cancer drug DepoCyte after fining manufacturing issues at a San Diego plant. Story

> Watson Pharmaceuticals ($WPI) says it believes it is entitled to 180-day exclusivity on its generic version of Endo Pharmaceutical's Lidoderm topical patch, which it will launch next under an agreement with Endo ($ENDP). Story

> Reports in a medical journal take Canadian officials to task for their poor response to drug shortages. Story

Biotech News

@FierceBiotech: New CEO tapped to run armed-antibody biotech Actinium. News | Follow @FierceBiotech

@JohnCFierce: Talked yesterday with Andrea Pfeifer of AC Immune, working on a new Alzheimer's drug with Roche. Said: We've got to move to earlier stage. | Follow @JohnCFierce

@RyanMFierce: A question now is how far will $LLY fall with sola failure, far enough for CEO John L. to change tune on internal R&D w/o mega-merger? | Follow @RyanMFierce

> GlaxoSmithKline ($GSK) says it has wrapped up studies of its LAMA/LABA therapy for COPD and is prepared to file for approvals as planned. The pharma giant is partnered with Theravance on the program. Story

> Synergy Pharmaceuticals has acquired FV-100, an experimental treatment for shingles, from Bristol-Myers Squibb ($BMY). Release

> The Leukemia & Lymphoma Society has provided $12 million in new grants for key research efforts. Release

Medical Device News

@FierceMedDev: Medtronic gained FDA approval and a CE mark for a new atrial fibrillation treatment. News | Follow @FierceMedDev

@MarkHFierce: LabCorp says no, but analysts believe the company is a buyout target for private equity firms--via Bloomberg. Report | Follow @MarkHFierce

@DamianFierce: Bolstered by Myriad's court decision, Rosetta is expanding its capacity and soaring on the Street. More | Follow @DamianFierce

> Tornier snags OrthoHelix for $135M. More

> Hybrid microscopy tech produces sharper imagery of the brain's finer details. Item

> Rosetta boosts capacity, soars on the Street. Article

And Finally... In case anyone in the world was unaware, Forest Laboratories ($FRX) announced the official results of its board elections, confirming that while 9 of its 10 members were re-elected, one of investor Carl Icahn's four nominees, Pierre Legault, joins the board. Release

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.